Skip to content

SG001

DRUG12 trials

Sponsors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd., CSPC Ouyi Pharmaceutical Co., Ltd., Shanghai JMT-Bio Inc., Shanghai Runshi Pharmaceutical Technology Co., Ltd, CSPC Megalith Biopharmaceutical Co.,Ltd.

Conditions

Advanced Biliary Tract CancerAdvanced Solid TumorAdvanced Solid TumorsAdvanced Solid TumoursCervical CancerEpithelial Ovarian CancerExtrahepatic CholangiocarcinomaFallopian Tube Cancer

Phase 1

Phase 2

Study of the SG001 Injection for Patients With Relapsed or Metastatic Uterine Cervical Cancer
NCT04886700
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Uterine Cervical Cancer
Start: 2021-07-31End: 2023-12-31Target: 104Updated: 2021-11-22
Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC
NCT04983550
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Start: 2021-09-30End: 2024-01-31Target: 126Updated: 2021-07-30
Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
TerminatedNCT05009953
CSPC Ouyi Pharmaceutical Co., Ltd.Advanced Biliary Tract Cancer, Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma +1
Start: 2021-09-01End: 2023-01-16Updated: 2024-07-11
A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)
NCT05068141
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Triple Negative Breast Cancer
Start: 2021-10-01End: 2023-10-01Target: 79Updated: 2021-10-15
A Study of JMT101 in Patients With Metastatic Colorectal Cancer
NCT06089330
Shanghai JMT-Bio Inc.Metastatic Colorectal Cancer (mCRC)
Start: 2024-01-31End: 2024-12-31Target: 102Updated: 2023-10-18
SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC
Not yet recruitingNCT06989671
CSPC Megalith Biopharmaceutical Co.,Ltd.Head and Neck Squamous Cell Carcinoma
Start: 2025-08-30End: 2028-07-30Target: 430Updated: 2025-08-27
Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)
RecruitingNCT07183865
Fudan UniversityLocally Recurrent Rectal Cancer
Start: 2025-03-09End: 2030-03-09Target: 44Updated: 2025-09-19

Related Papers